Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.
- FDA supports ~100-patient Phase 2b amsulostat trial
- $8 million placement extends cash runway to Q3 2027
- Preliminary SNT-4728 data shows significant inflammation reduction
- SNT-9465 hypertrophic scar trial over 60% recruited
- AZALOX MDS study advances to final Phase 1b dose cohort
FDA Endorsement Clears Path for Amsulostat Phase 2b Trial
Syntara Limited (ASX:SNT) achieved a pivotal regulatory milestone with positive feedback from the US FDA on its proposed Phase 2b trial of amsulostat in myelofibrosis. The agency backed the study design for approximately 100 patients whose disease remains uncontrolled by current JAK inhibitor therapy, endorsing a double-blind, placebo-controlled trial targeting a 50% symptom reduction over nine months. This endorsement not only validates the safety and efficacy profile established in the Phase 2a trial but also sharpens amsulostat’s commercial appeal as it advances toward late-stage development.
Capital Raise Strengthens Balance Sheet and Extends Runway
Backing its clinical ambitions, Syntara completed an $8 million institutional placement alongside a $0.84 million share purchase plan, collectively raising $8.84 million before costs. Priced at a 15.6% discount to the closing share price, the capital injection lifts the company’s cash balance to $13.5 million and extends its runway into the third quarter of 2027. These funds are earmarked to support five key clinical readouts across its pipeline, including amsulostat’s Phase 2b preparations, and to fuel ongoing licensing discussions and patent portfolio expansion.
Promising Preliminary Data from SNT-4728 in Parkinson’s-Related Disorder
Following quarter-end, Syntara reported encouraging early results from its Phase 2 trial of SNT-4728 in isolated REM Sleep Behaviour Disorder (iRBD), a prodromal stage of Parkinson’s disease. The trial demonstrated a statistically significant reduction in inflammation within the putamen, a brain region critical to motor symptoms, with 20 of 30 treated patients showing improvement. Broader imaging also revealed anti-inflammatory effects in temporal lobe areas linked to cognition. These findings, expected to be expanded upon with full data in Q3 2026, suggest SNT-4728’s potential to slow neurodegeneration by targeting inflammation.
Clinical Trials Progressing in Hypertrophic Scars and MDS
The Phase 1b trial of SNT-9465, a topical pan-lysyl oxidase inhibitor for hypertrophic scars, has surpassed 60% recruitment, with completion targeted in Q3 2026. The within-patient study design compares treated and placebo scar regions, aiming to produce the first approved drug specifically for skin scarring. Meanwhile, the AZALOX study evaluating amsulostat combined with 5-Azacitidine in high-risk myelodysplastic syndrome (MDS) advanced to its final dose cohort after safety data review. This dose escalation phase showed no dose-limiting toxicities, setting the stage for a Phase 2 efficacy evaluation.
Financials and Pending Payments from Mannitol Business Sale
Operating cash outflows remained steady at $3.6 million for the quarter, driven mainly by R&D ($2.1 million) and staff costs ($1.2 million). The company also continues to pursue payments related to its 2023 sale of the mannitol respiratory business to Arna Pharma, with outstanding claims now reduced to approximately $0.6 million amid ongoing reconciliation and partial payments. While the timing and quantum of these payments remain uncertain, they represent a modest potential cash inflow within the current financial year.
Bottom Line?
Syntara’s FDA-backed amsulostat trial and fresh capital position the company for a busy second half of 2026, with multiple clinical readouts poised to shape its development trajectory.
Questions in the middle?
- Will the full Phase 2 SNT-4728 data confirm the durability of its anti-inflammatory effects in iRBD?
- How swiftly can Syntara translate FDA feedback into trial initiation and patient recruitment for amsulostat’s Phase 2b study?
- What impact will the ongoing licensing discussions have on Syntara’s commercial strategy and valuation?